Dynamic Review On Various Approaches In Drug Discovery And Development

Gejalakshmi.S[1*], Harikrishnan.N[2]

[1*,2]Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Dr. MGR Educational and Research Institute Velappanchavadi, Chennai-77

***Corresponding Author:** Gejalakshmi.S

*Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Dr. MGR Educational and Research Institute Velappanchavadi, Chennai-77

Received Date:- 28/01/2023 **Revised Date**:- 15/02/2023 **Acceptance Date:-** 05/03/2023

Abstract:

Development of the new drugs generally starts with target selection followed by the identification, confirmation, lead optimization. The identification is an early stage in the whole drug discovery process. Virtual screening methods are becoming important in the drug discovery process. Random screening and rational design conventionally have shown a notable development in the drug discovery process leading to the recognition of ligands.

The Selected method of a short background precedes an assessment of the method with respect to the needs of drug discovery, and in particular work from China is highlighted. The selection or the design of new lead compounds and their modification to obtain better affinities, as well as pharmacokinetic and pharmacodynamic properties. Among the different tools available, a particular emphasis is placed on molecular docking, virtual high-throughput screening & fragment-based ligand design. The illustrate some of the in-silico methods for pharmacology that are used in drug discovery.

Initial evaluation of current drug candidates from various reports using systemic in silico drug screening based on structures of viral proteins and human ACE2 receptor. The homology modelling methodology allows the prediction of the 3D structure of a protein from its amino acid sequence.

The IC50 values of compounds 2a, a diterpene bearing polycyclic skeleton, and 3a, named Daphne one with chain scaffold, are as low as 1.29 and 1.79μM, respectively. Compared to the control compound guggulsterone (IC50 = 6.47μM), compounds 2a and 3a displayed 5- and 3-fold higher antagonistic activities against FXR, respectively.

CADD used to improve the drug development process. In the past discovery of new drugs was often conducted through the empirical observation of the effect of natural products in known diseases. The drug screening can also based upon the viral proteins and human AEC2 receptors.

Keywords: CADD, AEC2 receptors, Virtual screening, in-silico studies, ligands, Drug discovery process.

Introduction:

In Silico was shortly challenged by *In Silicio* which is correct Latin for *"in silicon"*. The Latin term for *silicon, silicium*. Computer aided drug design are the methodologies which major playing an ever-increasing role in drug design and discovery. The cost effect identification of the drug candidates, computational methods are relevant in limiting the use of animal models that are used in pharmacological research. The idea that are computational model of the chemical compound binding the modulating their receptors target are replace tedious. It has been expensive high throughout the screening method of assays for the drug discovery and design. Assay and synthesis would be needed but in the in-silico predictions would help to the dramatically narrow down the number of the compounds to make the assay in the test tube. The general economics of the computational driven drug discovery & design was never made to work at the scale in the past. In last couple of years in silico drug discovery can made in both industry and academia. Big pharma & biotech are expanding their CADD teams. Development of the new drugs generally starts with target selection followed by the identification, confirmation, lead optimization. The identification is an early stage in the whole drug discovery process. Screening requires a date base of chemical and searches this database in silico for identifying drug candidates. Screening can be applied as a compound selection filter for the identification of biological active compound. Virtual screening method can be regarded as an attempt to extend the concept of QSAR. Virtual screening method is a knowledge driven approach that requires the structural information either on bio active ligands for a target of an interest. Virtual screening methods are becoming important in the drug discovery process. This method is also one economic reason explaining why virtual screening are becoming more and more popular. Due to the limitations imposed by screening cost compared to the number of molecules potentially available for screening issue that can be only addressed by careful compound selections and design. During many attempts have been made in order to estimate the size of a drug like chemical space.

Most of these efforts may be categorized as the chance of discovery rather than a rational approach. The enthusiasm to embrace rational approaches is triggered in recent years following tremendous move forward in the computations and protein crystallography. In-silico approach have gained immense popularity and have become an integral part of the industrial and academic research, directing drug design and discovery. Computational tools, which delineate the strength of interaction between a variety of ligands and targets in combination with good graphic three-dimensional visualization,

are growing into an important technologies to pick up lead molecules from the databases. The first and foremost task in any of the rational approaches for a given disease can be assess into various metabolic pathways and selected the potential biological target. Computational approaches are noticeably important to guide the prospective experimentalists in the synthesis and screening of the compounds in a more rational way. Random screening and rational design conventionally have shown a notable development in the drug discovery process leading to the recognition of ligands. Drug discovery, such as medicinal and computational chemists, the strategy can be subdivided into two main types; Lead identification and lead optimization. It is also important to study pharmaco-kinetics, and toxicological profiles for in-vivo studies, which can be achieved by the screening procedures. Designing inhibitors for membrane proteins, which are major drug targets; the difficulties in the structure identification prompts one to employ a modelled structure. Likewise the other factors like water mediation at the interface of biomolecular complexes, and protonation states are vital in determining the drug interaction. It is also important to account for the metal ion-binding sites, the nature of the residues in the active site, and the changes that are affected to the biological receptor upon binding of drug molecules. High Throughput Screening (HTS) refers to the modern process whereby thousands of samples has been screened each day, against a given (known or unknown) target, essentially gauging the drug efficacy with the simple data value for each of the sample. HTS is a method to identify the new pharmacologically active compound on a massive trial and error basis, and requires learning about the possible targets and their interactions of ligands under the test. Recent progress in high-throughput screening, combinatorial chemistry and molecular biology have considerably changed the approach to the drug discovery in pharmaceutical industry. New challenges of the synthesis results in new analytical methods. Docking is a computationally challenging because of the many different ways in which two molecules may be arranged together to form a complex. Virtual screening can approach to use simplified representations (pharmacophores) of the candidate ligands and sometimes part of the protein surface. This allows very rapid selection or filtering of extremely large datasets of candidate drug molecules in silico methods to speed up lead identification and optimization. Up till now, these techniques have been contributed to the design of about 50 compounds that entered clinical trials, some of which are now FDA approved. Quantitative structure–activity relationship (QSAR) analysis in the early 1960s, the concept of CADD has develop very quickly, especially in the recent decade as an unprecedented development of structural biology and computer capabilities. CADD technologies including molecular modelling and simulation have become promising in the drug discovery. Recently, CADD has been even used in designing of highly selective ligands for a certain target that shares very similar structures with many proteins, which is difficult to be done by other methods. The postgenomic era, owing to the dramatic increase of small molecule and biomacromolecule information, CADD tools has been applied in almost every stage of drug R&D, greatly changing the strategy and pipeline for drug discovery. As indicated in CADD, from its traditional application of lead discovery and optimization, has extended toward two directions: upstream for target identification and validation, and downstream for preclinical study of ADMET prediction.

Reviewed Summary:

Mingyue Zheng.et.al[1]; reviewed about computational method for drug design and discovery. The Selected method of a short background precedes an assessment of the method with respect to the needs of drug discovery, and in particular work from China is highlighted. More several successful applications of these methods are illustrated. End with a discussion of current major challenges and future directions of the field.

Manuela S. Murgueitio.et.al[2]; reviewed about in silico virtual screening approaches for antiviral drugs. The rational approach makes the drug discovery process more goal-oriented and saves resources in terms of time and money. In different virtual screening techniques can be applied to antiviral drug discovery, present recent success stories in this field and finally address the main differences between the methods.

Vincent Zoete.et.al[3]; reviewed about in silico fragment based drug design. The selection or the design of new lead compounds and their modification to obtain better affinities, as well as pharmacokinetic and pharmacodynamic properties. Among the different tools available, a particular emphasis is placed in this review about the molecular docking, virtual high-throughput screening and fragment-based ligand design.

S Ekins.et.al[4]; reviewed about in silico pharmacology for drug discovery. Clarification of the absorption, distribution, metabolism, excretion and toxicity properties as well as physicochemical characterization. The illustrate some of the in-silico methods for pharmacology that are used in drug discovery. Further applications of these methods to specific targets and their limitations will be discuss.

Chi Xu.et.al[5]; reviewed about systemic in silico screening in drug discovery for corona virus. Initial evaluation of current drug candidates from various reports using systemic in silico drug screening based on the structures of viral proteins and human ACE2 receptor. Additionally, the results with the visual display of a small molecule docked on its potential target protein, without installing any specialized structural software. The continuous maintenance and incorporation of data from laboratory work, it may serve not only as the assessment tool for the new drug discovery but also an educational.

Xiaoqian Lin.et.al[6]; reviewed about applications of computational methods in drug design. The development of machine learning methods and their applications in afore mentioned computational methods to speed up the drug discovery process.

Also, several application examples of combining various methods were discussed. A combination of di-erent methods to jointly solve the tough problem at di-erent scales and dimensions will be the inevitable trend in drug screening and design.

Eduardo Habib Bechelane Maia.et.al[7]; reviewed about structure based virtual screening. The homology modelling methodology allows the prediction of the 3D structure of the protein from its amino acid sequence. Challenges involved in the use of CADD to perform SBVS, the areas where CADD tools support SBVS, a comparison between the most commonly used tools, and the techniques right now used in an attempt to reduce the time and cost in the drug development process.

Shuhua G. Li.et.al[8]; reviewed about hybrid screening approach to identify potent inhibitors for the SARS-CoV2. In vitro potency analyses validated several potent inhibitors and thus confirmed the feasibility of virtual screening strategy. Overall the several potent hit Mpro inhibitors, in which two inhibitors have IC50 values below 1 μM, that are worth being further optimized and explored. Meanwhile, the refined virtual screening strategy is also applicable to improve general in silico screening hit rates and its useful to accelerate drug discovery for treating COVID-19 and other viral infections.

Yangguang Liu.et.al[9]; reviewed about structural based screening of antiandrogen targeting activation. In-silico screening method and the subsequent biological evaluation lead to the discovery of the novel lead compound IMB-A6 that binds to the AF2 site, which inhibits the activity of either wild-type (WT) or resistance mutated ARs. The structure-based drug design is an efficient strategy to discover new antiandrogens, and provides a new class of small molecular antiandrogens for the development of novel treatment agents against PCa.

Eduardo Habib Bechelane Maia.et.al[10]; reviewed about structure based virtual screening. The challenges involved in the use of CADD to perform SBVS, the areas where CADD tools to support SBVS, a comparison between the most commonly used tools, and the techniques currently used in the attempt to reduce the time and cost in the drug development process. The considerations demonstrate the importance of the using SBVS in the drug development process.

Yanyan Diao.et.al[11]; reviewed about discovery of natural products as novel by virtual screening. The IC50 values of compounds 2a, a diterpene bearing polycyclic skeleton, and 3a, named Daphne one with chain scaffold, are as low as 1.29 and 1.79μM, respectively. Compared to the control compound guggulsterone (IC50 = 6.47μM), compounds 2a and 3a displayed as 5 and 3 fold higher antagonistic activities against the FXR, respectively. Remarkably, the two representative compounds shared the low topological similarities with other reported FXR antagonists. According to the putative binding poses of the molecular basis of these antagonists against FXR was also elucidated in this report.

Jonas Aretz.et.al[12]; reviewed about nuclear magnetic resonance-based fragment screening. The complete Relaxation and Conformational Exchange Matrix (CORCEMA) theory adapted for the saturation transfer (ST) measurements (CORCEMA-ST) calculations to predict STD NMR results from a large set of fragment or receptor to pairs to investigate the boundaries under which the assumption holds true that a high STD effect can be applied to select for higher-affinity fragments. The conclusion that this assumption is invalid.

Lirui Lin.et.al[13]; reviewed about marine natural products by virtual screening. ligand Gaussian accelerated molecular dynamics (LiGaMD) simulations were carried out to validate the three inhibitors binding to Fascine stably. In dynamic interactions between protein and ligands were analyzed systematically. Accelerate of the development of the cancer drugs targeting Fascin.

Gaspar P. Pinto.et.al[14]; reviewed about fast screening inhibitor using novel software tool. The screening identified the functional tunnels based on the profile of potential energies of binding and unbinding trajectories. We concluded that Caver Dock is a sufficiently fast, robust, and accurate tool for screening binding/unbinding processes of pharmacologically important targets with buried functional sites.

Mariela Bollini.et.al[15]; reviewed about discovery of novel bovine viral diarrhoea inhibitors by using structure based virtual screening methods. The compounds their possible binding determinants were characterized by molecular dynamics simulations. A common pattern of interactions between active molecules and amino acid residues in the binding site in E2 was observed. These findings could offer a better understanding of the interaction of the BVDV E2 with these inhibitors, as well as benefit of discovery of novel and more potent BVDV antivirals.

Leidy L. García-Ariza.et.al[16]; reviewed about virtual screening of drug like compounds. Compounds are interact mainly with the amino acids of the catalytic sites and involved in processes of protein activity. The identified compounds are presented physicochemical and the pharmacological properties of interest for their use as possible drugs; furthermore, we found that some of these compounds does not affect the cell viability in Huh-7; therefore, we suggest evaluating these compounds in vitro as candidates in the future research.

Aman C. Kaushik.et.al[17]; reviewed about structure based virtual screening studies to identify novel potential compounds for GPR142. The biochemical pathway of GPR142 complex with screened compound was also designed and compared with experimental data. Interestingly, compound showed an increase in insulin production via Gq mediated signaling pathway suggesting the possible role of novel GPR142 agonists in therapy against type 2 diabetes.

Shan-Kui Liu.et.al[18]; reviewed about discovery of new α – glucosidase inhibitors using structure based virtual screening. The binding modes of these four compounds are carefully investigated. Significantly, these four compounds showed the nontoxicity (IC50 > 100 μM) toward the human normal hepatocyte cell line (LO2), which indicated the potential of developing into novel candidates for type 2 diabetes treatment.

Imogen L. Christopher.et.al[19]; reviewed about computational screening for new energetic molecules. The local vibrational mode analysis has been used to calculate the bond length/force constant curves for seven different chemical bonds occurring in the CHNO containing molecules, which allow for the rapid identification of the weakest bond, opening up great potential to rationalise decomposition pathways. Both metrics are the important tools in rationalising the design of new energetic materials through computational screening processes.

Muhammad Akram.et.al[20]; reviewed about pharmacophore modelling and in silico / in vitro screening for human. The virtual screening of the SPECS database was performed with our pharmacophore queries. Biological evaluation of the selected hits leads to the discovery of three potent novel inhibitors of both CYP11B1 and CYP11B2 in the sub micromolar range (compounds 8–10), one selective CYP11B1 inhibitor [Compound 11, IC50 = 2.5μM], one selective CYP11B2 inhibitor [compound 12, IC50 = 1.1μM], respectively. The overall success rate of this prospective virtual screening experiment is 20.8% indicating good predictive power of the pharmacophore models.

Jiacheng Xiong.et.al[21]; reviewed about structure based virtual screening. The NanoBiT, assays and the surface plasmon resonance (SPR) assays demonstrated their capabilities of blocking SARS-CoV-2 S-RBD/ACE2 interaction and directly binding to both S-RBD and ACE2. Moreover, the pseudo virus assay revealed that these two compounds possessed significant antiviral activity. The results indicate that the compounds DC-RA016 and DC-RA052 are promising inhibitors against SARS-CoV-2 S-RBD/ACE2 interaction and deserve to be further developed.

Jian Liang Low.et.al[22]; reviewed about screening of the tb actives for activity. study showed that screening TB active compounds for activity against the NTM resulted in high hit rates, suggesting that this may be an attractive approach to the kick start NTM drug discovery projects. In addition, the work identified a series of the novel high value NTM hits with the associated candidate targets which can be followed up in hit-to-lead projects for the discovery of new the NTM antibiotics.

Divya Gupta.et.al[23]; reviewed about structure based screening of non β lactam inhibitors. Structure-based virtual screening using an docking programs and molecular dynamics simulations was employed to the identify two novel non-β-lactam compounds that possess the ability to block the different OXA variants. Furthermore, the presence of a nonpolar aliphatic amino acid, valine, near the active site serine, was identified in all the OXA variants that can be accounted to block the catalytic activity of OXA enzymes.

Rohan Gupta.et.al[24]; reviewed about the machine intelligence approach for drug discovery. Evidence from the past strengthens the implementation of the artificial intelligence and deep learning in this field. Moreover, the novel data mining, curation, and the management techniques provided critical support to recently developed modelling algorithms. In summary, the artificial intelligence and deep learning advancements provide an excellent opportunity for rational drug design and discovery process, which will eventually impact mankind.

Rhythm Bharti.et.al[25]; reviewed the molecules against covid 19 an Insilco approach for drug discovery. The docked results have clearly shown binding of the ligands to SARS-CoV-2 RdRp protein. Interestingly, all the ligands were found to obey Lipinski's rule of five. These results provide a basis for repurposing and using the molecules, derived from the plants and animals, as a potential treatment for the coronavirus disease 2019 (COVID-19) infection as they could be effective therapeutics for the same.

CONCLUSION:

CADD used to improve the drug development process. In the past, the discovery of the new drugs was often conducted through the empirical observation of the effect of natural products in known diseases. Therefore, the more several successful applications of these methods are illustrated. Conclude with a discussion of current major challenges and the future directions of the field. The various authors were explained about the In-silico studies of drug design and development. It may also explained about the mechanism of action such as absorption, distribution, metabolism elimination and toxicity properties of the given drug. The in-silico methods of pharmacology can also used in drug discovery due to its mechanism of action. The drug screening can also based on viral proteins and human AEC2 receptors. The targeted protein can be docked without any software bases. The evidences of artificial intelligence and get deep

learning from this field. Thus the in-silico properties of drug discovery and development was identified by using the various files from software.

REFERENCE:

1. Mingyue Zheng, Xian Liu, Yuan Xu, Honglin Li, Cheng Luo, and Hualiang Jiang. Computational methods for drug design and discovery focus on China. Trends in Pharmacological Sciences 2013, Vol. 34, No. 10
2. Manuela S. Murgueitio, Marcel Bermudez, Je re mie Mortier, Gerhard Wolber. In silico virtual screening approaches for antiviral drug discovery. Vol. 9, No. 3 2012
3. Vincent Zoete , Aurelien Grosdidier , Olivier Michielin. Docking, virtual high throughput screening in silico fragment-based drug design. J. Cell. Mol. Med. Vol 13, No 2, 2009.
4. S Ekins1, J Mestres and B Testa. In silico pharmacology for drug discovery methods for virtual ligand screening and profiling. British Journal of Pharmacology 2007 152, 9–20.
5. Chi Xu , Zunhui Ke , Chuandong Liu , Zhihao Wang , Denghui Liu , Lei Zhang , Jingning Wang , Wenjun He , Zhimeng Xu , Yanqing Li , Yanan Yang , Zhaowei Huang , Panjing Lv , Xin Wang , Dali Han , Yan Li , Nan Qiao , and Bing Liu. Systemic In Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server. J. Chem. Inf. Model. 2020, 60
6. Xiaoqian Lin , Xiu Li and Xubo Lin . A Review on Applications of Computational Methods in Drug Screening and Design . Molecules 2020, 25, 1375
7. Eduardo Habib Bechelane Maia , Letícia Cristina Assis , Tiago Alves de Oliveira , Alisson Marques da Silva and Alex Gutterres Taranto. Structure-Based Virtual Screening From Classical to Artificial Intelligence. Frontiers in Chemistry , 2020 , Volume 8
8. Shuhua G. Li , Kai S. Yang , Lauren R. Blankenship , Chia-Chuan D. Cho , Shiqing Xu , Hongbin Wang and Wenshe Ray Liu. An Enhanced Hybrid Screening Approach to Identify Potent Inhibitors for the SARS-CoV-2 Main Protease From the NCI Compound Library.
9. Yangguang Liu , Meng Wu , Tianqi Wang , Yongli Xie , Xiangling Cui , Liujun He , Yang He , Xiaoyu Li , Mingliang Liu , Laixing Hu , Shan Cen and Jinming Zhou. Structural Based Screening of Antiandrogen Targeting Activation Function-2 Binding Site. Frontiers in Pharmacology 2018 Volume 9.
10. Eduardo Habib Bechelane Maia , Letícia Cristina Assis , Tiago Alves de Oliveira , Alisson Marques da Silva and Alex Gutterres Taranto. Structure-Based Virtual Screening From Classical to Artificial Intelligence. Frontiers in Chemistry 2020 Volume 8
11. Yanyan Diao , Jing Jiang , Shoude Zhang , Shiliang Li , Lei Shan , Jin Huang , Weidong Zhang and Honglin Li. Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening. Frontiers in Chemistry 2018 Volume 6
12. Jonas Aretz and Christoph Rademacher.Ranking Hits From Saturation Transfer Difference Nuclear Magnetic Resonance Based Fragment Screening. Frontiers in Chemistry 2019 Volume 7
13. Lirui Lin , Kai Lin , Xiaodong Wu , Jia Liu , Yinwei Cheng , Li-Yan Xu , En-Min Li and Geng Dong. Potential Inhibitors of Fascin From A Database of Marine Natural Products A Virtual Screening and Molecular Dynamics Study. Frontiers in Chemistry 2021 , Volume 9.
14. Gaspar P. Pinto , Ondrej Vavra , Jiri Filipovic , Jan Stourac , David Bednar and Jiri Damborsky. Frontiers in Chemistry 2019 Volume 7
15. Mariela Bollini , Emilse S. Leal , Natalia S. Adler , María G. Aucar , Gabriela A. Fernández , María J. Pascual , Fernando Merwaiss , Diego E. Alvarez and Claudio N. Cavasotto. Discovery of Novel Bovine Viral Diarrhea Inhibitors Using Structure-Based Virtual Screening on the Envelope Protein E2. Frontiers in Chemistry 2018, Volume 6.
16. Leidy L. García-Ariza , Cristian Rocha-Roa , Leonardo Padilla-Sanabria and Jhon C. Castano-Osorio. Virtual Screening of Drug-Like Compounds as Potential Inhibitors of the Dengue Virus NS5 Protein. Frontiers in Chemistry 2022 Volume 10.
17. Aman C. Kaushik , Sanjay Kumar , Dong Q. Wei and Shakti Sahi. Structure Based Virtual Screening Studies to Identify Novel Potential Compounds for GPR142 and Their Relative Dynamic Analysis for Study of Type 2 Diabetes. Frontiers in Chemistry 2018 , Volume 6.
18. Shan-Kui Liu , Haifang Hao , Yuan Bian , Yong-Xi Ge , Shengyuan Lu , Hong-Xu Xie , Kai-Ming Wang , Hongrui Tao , Chao Yuan , Juan Zhang , Jie Zhang , Cheng-Shi Jiang and Kongkai Zhu.
19. Imogen L. Christopher , Adam A. L. Michalchuk , Colin R. Pulham and Carole A. Morrison. Towards Computational Screening for New Energetic Molecules Calculation of Heat of Formation and Determination of Bond Strengths by Local Mode Analysis. Frontiers in Chemistry 2021 , Volume 9
20. Muhammad Akram , Watcharee Waratchareeyakul , Joerg Haupenthal , Rolf W. Hartmann , and Daniela Schuster. Pharmacophore Modeling and in Silico / in Vitro Screening for Human Cytochrome P450 11B1 and Cytochrome P450 11B2 Inhibitors. Frontiers in Chemistry 2017, Volume 5
21. Jiacheng Xiong , Yusen Xiang , Ziming Huang , Xiaohong Liu , Mengge Wang , Guangbo Ge , Hongzhuan Chen , Jianrong Xu , Mingyue Zheng and Lili Chen. Structure-Based Virtual Screening and Identification of Potential Inhibitors of SARS-CoV-2 S-RBD and ACE2 Interaction. Frontiers in Chemistry 2021, Volume 9

22. Jian Liang Low, Mu-Lu Wu , Dinah Binte Aziz , Benoit Laleu and Thomas Dick. Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit Rates. Frontiers in Microbiology 2017, Volume 8
23. Divya Gupta, Aditi Singh, Pallavi Somvanshi, Ajeet Singh, and Asad U. Khan. Structure-Based Screening of Non-β-Lactam Inhibitors against Class D β-Lactamases: An Approach of Docking and Molecular Dynamics. ACS Omega 2020, Volume 5
24. Rohan Gupta, Devesh Srivastava , Mehar Sahu , Swati Tiwari , Rashmi K. Ambasta , Pravir Kumar. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular Diversity 2020, Volume 25.
25. Rhythm Bharti, Sandeep Kumar Shukla. Molecules against Covid-19: An in-silico approach for drug development. Journal of Electronic Science and Technology 19 (2021).